- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Parity Laws and the Need for Payment Reform
During this segment, Scott Gottlieb, MD; Brian Kiss, MD; Michael Kolodziej, MD; and Ted Okon, MBA, continue the discussion regarding issues that affect new oncology care models, including drug wastage, patient compliance, and treatment costs.
As more oncology drugs are being dispensed via practice-based pharmacies, intervention is needed to reduce waste, Dr Kolodziej comments. Also, compliance remains an issue even with the advent of practice-based pharmacies.
Although some states have passed parity laws, meaning that patient out-of-pocket (OOP) costs for oral medications should not be greater than OOP costs for intravenous medications, high OOP costs remain a barrier to patient access to treatment.
Dr Kiss discusses the buy-and-bill model’s impact on oncology and suggests that payment reform is necessary. Oncologists should be compensated for providing cognitive and technical services, he believes, rather than for dispensing chemotherapy drugs.
Gefurulimab for gMG Meets Key End Points in PREVAIL Trial
July 28th 2025The primary endpoint in PREVAIL is Myasthenia Gravis-Activities of Daily Living total score improvement from baseline, and the secondary endpoints are Quantitative Myasthenia Gravis total score and Myasthenia Gravis Composite total score.
Read More
